Competitive and market landscape for CAR T-cell therapy Challenge A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrita to conduct a comprehensive competitive landscape to better understand the current CAR T-cell therapy space. The company wanted to understand the product profiles of top CAR T-cell therapies in development, current challenges in the field and solutions other companies are employing, as well as the deals landscape. This would help guide their business and product development strategy to maximize the value of their technology. Solution Alacrita conducted a comprehensive review of top products launched and in development, including bb-2121 (Bluebird/Celgene), UCART-19 (Cellectis), JCAR- 017 and JCAR-015 (Juno), CTL019

Join for free to read